We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-0.95%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$55.7B
AUM Growth
+$1.33B
Cap. Flow
+$2.27B
Cap. Flow %
4.08%
Top 10 Hldgs %
19.71%
Holding
3,688
New
269
Increased
1,855
Reduced
1,236
Closed
227

Sector Composition

Rank Sector Weight
1 Technology 10.05%
2 Financials 9.3%
3 Healthcare 7.74%
4 Industrials 6.94%
5 Communication Services 5.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NMZ icon
2201
Nuveen Municipal High Income Opportunity Fund
NMZ
$2.22B
$895K ﹤0.01%
71,633
-12,382
-15% -$162K
SINA
2202
DELISTED
Sina Corp
SINA
$895K ﹤0.01%
+8,582
New +$984K
PLUS icon
2203
ePlus
PLUS
$2.31B
$894K ﹤0.01%
+23,024
New +$887K
TWLO icon
2204
Twilio
TWLO
$38.3B
$892K ﹤0.01%
23,359
-73,134
-76% -$2.32M
ATO icon
2205
Atmos Energy
ATO
$28.7B
$890K ﹤0.01%
10,566
-30,431
-74% -$2.48M
MMT
2206
Aberdeen Multi-Market Income Fund
MMT
$244M
$888K ﹤0.01%
153,948
-91,667
-37% -$538K
ACH
2207
Accendra Health
ACH
$84.6M
$888K ﹤0.01%
57,127
+7,372
+15% +$131K
SPLB icon
2208
State Street SPDR Portfolio Long Term Corporate Bond ETF
SPLB
$1.19B
$888K ﹤0.01%
32,580
-67,217
-67% -$1.85M
EWRM
2209
DELISTED
GUGGENHEIM RUSSELL MIDCAP EQUAL WEIGHT ETF
EWRM
$886K ﹤0.01%
14,056
-5,205
-27% -$328K
PXF icon
2210
Invesco FTSE RAFI Developed Markets ex-US ETF
PXF
$2.98B
$885K ﹤0.01%
19,824
-14,615
-42% -$672K
AXDX
2211
DELISTED
Accelerate Diagnostics
AXDX
$883K ﹤0.01%
3,864
+35
+0.9% +$9.19K
HLI icon
2212
Houlihan Lokey
HLI
$9.24B
$883K ﹤0.01%
19,789
+4,166
+27% +$197K
SXT icon
2213
Sensient Technologies
SXT
$5.53B
$883K ﹤0.01%
12,510
+2,745
+28% +$198K
UDR icon
2214
UDR
UDR
$12.2B
$883K ﹤0.01%
24,784
-2,324
-9% -$81.9K
DBI icon
2215
Designer Brands
DBI
$312M
$882K ﹤0.01%
+39,274
New +$807K
DNP icon
2216
DNP Select Income Fund
DNP
$4.11B
$882K ﹤0.01%
85,831
-35,666
-29% -$369K
RMT
2217
Royce Micro-Cap Trust
RMT
$780M
$879K ﹤0.01%
93,961
-67,348
-42% -$641K
IOVA icon
2218
Iovance Biotherapeutics
IOVA
$2.95B
$878K ﹤0.01%
+51,973
New +$787K
EPC icon
2219
Edgewell Personal Care
EPC
$1.31B
$876K ﹤0.01%
17,943
+8,480
+90% +$457K
ASX icon
2220
ASE Group
ASX
$103B
$874K ﹤0.01%
120,410
+7,934
+7% +$55.6K
SANM icon
2221
Sanmina
SANM
$11.1B
$874K ﹤0.01%
33,410
+1,521
+5% +$43.5K
VKQ icon
2222
Invesco Municipal Trust
VKQ
$550M
$871K ﹤0.01%
74,470
-7,612
-9% -$91.3K
MTRN icon
2223
Materion
MTRN
$5.88B
$870K ﹤0.01%
17,044
+9,545
+127% +$487K
CASH icon
2224
Pathward Financial
CASH
$1.79B
$869K ﹤0.01%
23,868
+2,058
+9% +$73.6K
EWQ icon
2225
iShares MSCI France ETF
EWQ
$332M
$869K ﹤0.01%
27,672
-6,750
-20% -$216K

Similar funds

Raymond James & Associates's Q1 2018 Portfolio in Review

As of Q1 2018, Raymond James & Associates held 3,688 positions worth $55.7B, up 2.4% from $54.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Raymond James & Associates deployed $2.27B of net new capital in Q1 2018, opening 269 new positions and adding to 1,855 existing holdings. Its largest new stake was Nutrien: 608,282 shares worth $28.7M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, up from 9.7% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was AbbVie, an estimated $68.1M trimmed.

  • Raymond James & Associates's largest Q1 2018 buy was Nutrien: 608,282 shares worth $28.7M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q1 2018, an estimated $211M increase.
  • Raymond James & Associates's biggest Q1 2018 reduction was AbbVie, cutting an estimated $68.1M.
  • Raymond James & Associates fully exited Regal Entertainment Group in Q1 2018, selling an estimated $48.4M.
  • Raymond James & Associates's ten largest holdings make up 20% of its $55.7B portfolio in Q1 2018.
  • Raymond James & Associates opened 269 new positions and closed 227 in Q1 2018.
  • Raymond James & Associates's portfolio value rose 2.4% quarter-over-quarter to $55.7B.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.